Ovarian cancer in endometriosis: clinical and molecular aspects.

B Lyttle, Brianna Lyttle, L Bernardi, Lia A. Bernardi, Mary Ellen Pavone, M E Pavone
Minerva ginecologica · 2014 · vol. 66(2) , pp. 155–64 · PMID:24848074 · W2302834983
article OA: green CC0 ⤵ 8 in-corpus citations
View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This review covers recent clinical and molecular findings on ovarian cancer in endometriosis patients, including early presentation, tumor characteristics, and associated genetic mutations like PTEN and ARID1A.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Endometriosis is a gynecological condition characterized by specific histological, molecular and clinical findings, that affects 5-10% of premenopausal women and has been implicated as a precursor for certain types of ovarian cancer. Clinical studies of endometriosis associated ovarian cancer (EAOC) suggest that patients present at a young age with a lower stage and grade of tumor, and are more likely to be premenopausal than women with other ovarian cancers. However, when overall survival is compared between these types of ovarian cancers, there is no difference noted. In addition, EAOC tumors are more likely to be found with a concurrent diagnosis of cancer, most commonly endometrial. Advances in technology, primarily the ability for whole genome sequencing, have led to the discovery of new mutations and further understanding of previously identified genes and pathways associated with EAOCs including PTEN, CTNNB1 (beta-catenin), KRAS, microsatellite instability and ARID1A. This paper will review the most recent clinical and molecular advances in the association of endometriosis and ovarian cancer.

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Endometriosis Ovarian Neoplasms Premenopause Age Factors Endometriosis Endometriosis Female Humans Microsatellite Instability Mutation Neoplasm Grading Neoplasm Staging Ovarian Neoplasms Ovarian Neoplasms Ovarian Neoplasms Survival Rate

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (64)

Cited by (8)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:18:29.016410+00:00
License: CC0 · commercial use OK